**1986 - FOUNDOING OF IBA**

Founded by Yves Jongen in 1986, IBA is as a spin-off of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve (UCL), Belgium. Initially active in medical imaging, the company turned its attention to radiotherapy and developed cyclotrons and integrated Proton therapy centers which are able to treat numerous forms of cancer with a degree of precision and efficacy never reached before.

**1991 - IBA revolutionizes the proton therapy world**

In 1991 IBA introduces a cyclotron revolutionizing the world of proton therapy. The IBA isochronous cyclotron-based solution is today the simplest and most effective way to produce 230 MeV protons and will be used in more than 25 Proton therapy centers all over the world.

**1992 - IBA expands its activities into sterilization and ionization**

In 1992, IBA expands activities into the industrial sector of sterilization and ionization by introducing the Rhodotron®, a new type of particle accelerator producing an electron beam based on a patented concept of the French Atomic Energy Commission.

**1997 - Employee buyout**

IBA employees got together in 1997 in an employee buyout of the shares of the company. The purpose was to raise their involvement in, and reward their commitment to, the success of the company while also giving themselves the opportunity to drive its future.

**1998 - IBA enters the Brussels stock market**

In June 1998, funds are raised on the Brussels stock market from an initial public offering to enable IBA to accelerate development through internal growth and acquisitions.

**1999 - IBA consolidates its strength in irradiation technology**

IBA consolidates its strength in irradiation technology with the acquisition by Ion Beam Applications of Radiation Dynamics, Inc. in February 1999. RDI was well-established in the field of high-power low-energy E-beam accelerators used for heat shrinking and polymer modification applications.

**2001 - IBA develops its presence in the radiopharmaceutical sector - acquisition of Eastern Isotopes**

In 2001, IBA becomes the majority shareholder of Eastern Isotopes, Inc., founded in 1993 in Sterling, Virginia, USA. Eastern Isotopes produces standard nuclear medicine products, while expanding into new PET imaging products, most notably FDG. The acquisition allows IBA to leverage its global expertise and innovation, and to offer its customers an international distribution network, more research isotopes and greater access to advanced cyclotron technology.

**2001 – First patient treated in an IBA clinical Proton Therapy (PT) center at MGH**

The first patient is treated with a PT system installed by IBA at the Massachusetts General Hospital, Boston, now known as Francis H. Burr Proton Therapy Center, in 2001. Since then, through relentless effort and commitment, IBA has installed over half of the clinically driven PT centers worldwide and has become the undisputed leader in the field.

**2004 – Expansion of proton therapy centers treating patients**

In 2004, the Indiana University Health Proton Therapy Center in Bloomington, Indiana (USA) treats its first patient using protons. A few months later, the Wanjie Proton Therapy Center in Zibo, China, starts treating patients with protons.

**2006 - For its 20th anniversary IBA focuses on the fight against cancer**

On April 20th 2006, IBA reveals its new corporate identity expressing its focus on the fight against cancer and its mission to Protect, Enhance and Save Lives. The different companies acquired throughout the years and IBA core activities are integrated in business units to form today's worldwide group.

**2007 - Developing presence in Asia**

In June 2007, IBA opens a new facility in Beijing, China, giving the company Asian Headquarters to support all its business units in Asia. This move is part of an overall development program to optimize opportunities in one of the world’s fastest growing markets.

**2006-2008 - IBA develops its presence in Europe**

IBA activities for the production and distribution of radiopharmaceuticals are developed in Europe through the acquisition of the Schering radiopharmaceutical business and CIS bio International, making IBA the largest European PET radio-isotopes network. As a second step, in 2008, IBA fully acquires the CISBIO organization with a complete line of SPECT radiopharmaceuticals and additional FDG production facilities. The acquisition of CISBIO makes the company one of the world's largest players in the radiopharmaceutical business.
2008 – Treating with Pencil Beam Scanning

In 2008, the highly precise treatment mode “Pencil Beam Scanning”, developed in collaboration with Massachusetts General Hospital (MGH), is approved by the U.S. Food and Drug Administration. A few months later, physicians at MGH’s Francis H. Burr Proton Therapy Center use Pencil Beam Scanning to treat patients.

2008 – IBA invests in cutting-edge medical technology

IBA invests in cutting-edge medical technology: acquisition of CISBIO’s drug discovery activities. For more than 25 years, CISBIO Bioassays, now a member of the IBA Group, has explored biology and immunosassay design to provide physicians, biologists, clinical chemists and scientists with enhanced solutions for improving patient care. CISBIO Bioassays dedicates its expertise to delivering cutting-edge assays and services to clinical medicine and pharmaceutical research.

2009 – Successful developments in proton therapy

In 2009, IBA’s proton therapy activity continues to grow with more successful developments in the field. The four beam modes of IBA’s Universal Nozzle, an all-in-one integrated system to treat patients, are utilized by physicians. Physicians at ProCure Treatment Center in Oklahoma City, Oklahoma (USA) use the new Inclined-beam Treatment Room and deploy the new Empath® 360° gantry room to treat patients.

2012 – IBA Refocuses its activities on MedTech equipment Company

In 2012, IBA opened a new chapter in its history with the refocus of its activities on its core business, proton therapy. This refocus will enable IBA to position itself for the future and consolidate its dominant position in a proton therapy market with high growth potential.

May 9,012 – Olivier Legrain appointed as Chief Executive Officer of IBA

Olivier Legrain takes on the role of Chief Executive Officer of IBA Group and succeeds to Pierre Mottet. Olivier Legrain joined the company in 1996 as financial controller. He then developed as President of IBA Dosimetry business from 1999 to 2003, President of IBA Molecular business from 2003 till 2010 and Chief Strategy Officer of the Group.

2013 – Yves Jongen nominated for the European Inventor Award

Yves Jongen, Founder and Chief Research Officer of IBA, is nominated for the European Inventor of the Year Award from the European Patent Office for his lifetime contribution to developing new solutions in proton therapy and making this next generations targeted cancer treatment more accessible to cancer patients worldwide.

2013 – IBA Group sells Cisbio Bioassays

Following its strategy to focus on its proton therapy, accelerators and dosimetry activities, IBA sells Cisbio Bioassays, to Argos Soditic. Cisbio Bioassays develops and markets products and technologies used for in vitro diagnostics and drug discovery.

2014 – FDA Approval for the new Compact Gantry

IBA receives Marketing Authorization from the U.S. Food and Drug Administration (FDA) for its Compact Gantry Beam Line. IBA anticipates that this regulatory approval will intensify the international interest in Proteus®ONE, IBA’s next generation proton therapy compact system.

2014 – IBA and Philips join forces to advance diagnosis and treatment of cancer

IBA and Philips sign a global collaboration to provide advanced diagnostic and therapeutic solutions for the treatment of cancer. This collaboration covers sales, marketing, research and development (R&D) of imaging and therapy solutions in oncology. IBA and Philips will provide more personalized diagnosis and therapy solutions for cancer patients.

2014 – First patient treated with IBA’s Proton Therapy Compact Solution Proteus®ONE.

The first patient has been treated with IBA’s compact proton therapy solution, Proteus®ONE, at the Willis-Knighton Cancer Center (WKCC) in Shreveport, Louisiana, USA.

2015 – IBA and Toshiba sign strategic partnership in particle therapy

IBA and Toshiba Corporation sign a global collaboration to expand access to advanced particle therapy worldwide. Toshiba Medical Systems Corporation will become the distributor in Japan for Proteus®ONE, and IBA will become the agent for Toshiba’s Carbon Therapy Solutions outside Japan.